🚀 go-pugleaf

MERCK RESPONDS:

Note from Ilena Rosenthal:  I wanted to capture this in its entirety
before it got "disappeared." Identical propaganda here on Usenet and
Wikipedia being used.

http://ilena-rosenthal.blogspot.com

His claim about the "placebo" doesn't mention that the placebo also
contained aluminum. 

Why was that???

I see identical wording as the PR giants have used for claiming the
safety of unsafe breast implants. 

http://www.newswire.ca/en/releases/archive/August2007/20/c8521.html
Merck Frosst responds to Maclean's 
    /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
    DISSEMINATION IN THE UNITED STATES/

    MONTREAL, Aug. 20 /CNW Telbec/ - A response based on scientific
facts to
the article on the front page of the August 27 issue of Maclean's was
published, Friday August 17, on the Merck Frosst Web site. To view the
complete response, please visit: www.merckfrosst.ca.
    "We are greatly troubled by the apparently biased journalism of
Maclean's. To gamble with the health of millions of Canadian women by
raising
unfounded fears and exaggerating safety concerns about one of the most
extensively tested vaccines is, in my mind, irresponsible," said Dawn
Graham,
President of Merck Frosst Canada Ltd. "There is no question that HPV
affects
many Canadian lives and the tolerability profile of Gardasil(R) is
excellent."

    Impact of HPV in Canada

    Three in four (75 per cent) sexually active Canadians will have at
least
one HPV infection episode in their lifetime.(1) HPV infections
annually lead
to approximately 400,000 abnormal Pap smear results(2), 85,000
consultations
due to genital warts and 36,000 new cases of genital warts(3), as well
as
1,400 cervical cancer diagnoses and 400 cervical cancer deaths.(4)
    HPV is also linked to other cancers in both men and women, such as
cancer
of the penis, anus, vagina and vulva, as well as loss of female
fertility and
premature ovarian failure.(5) According to the Society of
Obstetricians and
Gynaecologists of Canada, the incidence of cervical cancer is on the
rise in
Canada.(6)

    Comprehensive clinical research program

    Gardasil(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16,
18)
Recombinant Vaccine) clinical data is supported by one of the most
extensive
research programs for a vaccine in terms of number of subjects studied
and
length of evaluation. The vaccine has been studied for over five years
in
clinical trials involving close to 25,000 people in 33 different
countries. So
far 80 countries, including Canada, have approved Gardasil(R) on the
merits of
the scientific data.
    In clinical trials the vaccine was shown to be 96 to 100 per cent
effective at preventing infections from the HPV types that cause the
most
clinical diseases: HPV 6, 11, 16 and 18. These HPV types account for
more than
90 per cent of genital warts, approximately 70 per cent of cervical
and
anogenital cancers and high-grade pre-cancers, 35 to 50 per cent of
low-grade
cervical, vaginal and vulvar lesions, and all four types cause
abnormal Pap
test results.(7)
    The clinical trials found no increased number of serious adverse
events
in vaccinated subjects compared to placebo. Given that over ten
million doses
of Gardasil(R) have been distributed in the US, many of the reported
adverse
events in that country likely occurred coincidentally following
vaccination.
In particular, the often mentioned Guillain-Barre Syndrome (GBS) is a
naturally occurring event which can lead to paralysis and occurs in
approximately 3 of every 100,000 people each year in the US.(8) To
date, the
rate of GBS reported among people who received the vaccine is
consistent with
what you would expect to see in the population.

    Approved, recommended and endorsed

    Gardasil(R) has been approved by Health Canada and recommended by
the
National Advisory Committee on Immunization, a Canadian committee of
recognized experts in the fields of pediatrics, infectious diseases,
immunology, medical microbiology, internal medicine and public health.
The
vaccine has also been endorsed by the Society of Obstetricians and
Gynaecologists of Canada, the Society of Gynecologic Oncologists of
Canada and
the Society of Canadian Colposcopists.
    Canada's Chief Public Health Officer, Dr. David Butler-Jones,
recently
acknowledged that "...unfortunately, we tend to only have this debate
when we
are considering prevention measures, despite the fact that history has
repeatedly demonstrated that public health efforts designed to prevent
illness
and death are consistently safer, more effective and less costly than
treatment."(9)

    About Merck Frosst

    At Merck Frosst, patients come first. Merck Frosst Canada Ltd. is
a
research-driven pharmaceutical company. Merck Frosst discovers,
develops and
markets a broad range of innovative medicines to improve human health.
Merck
Frosst is one of the top 20 R&D investors in Canada, with an
investment of
$114 million in 2006. The Company is committed to fostering
partnerships to
deliver the most valuable health outcomes for Canadian patients. More
information about Merck Frosst is available at
http://www.merckfrosst.com.

    Forward-Looking Statement

    This press release contains "forward-looking statements" as that
term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks
and uncertainties, which may cause results to differ materially from
those set
forth in the statements. The forward-looking statements may include
statements
regarding product development, product potential or financial
performance. No
forward-looking statement can be guaranteed, and actual results may
differ
materially from those projected. Merck undertakes no obligation to
publicly
update any forward-looking statement, whether as a result of new
information,
future events, or otherwise. Forward-looking statements in this press
release
should be evaluated together with the many uncertainties that affect
Merck's
business, particularly those mentioned in the cautionary statements in
Item 1
of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its
periodic
reports on Form 10-Q and Form 8-K, which the Company incorporates by
reference.

    <<
    ---------------------------------------
    (1) Health Canada, It's Your Health HPV Web site. (Accessed at
 http://www.hc-sc.gc.ca/iyh-vsv/diseases-maladies/hpv-vph_e.html).
    (2) Statement by the Society of Obstetricians and Gynaecologists
of
        Canada (SOGC) on CMAJ Commentary, "Human papillomavirus,
vaccines and
        women's health: questions and cautions". (Accessed on August
14, 2007
        at: http://www.sogc.org/media/guidelines-hpv-commentary_e.asp)
    (3) Brisson, M et al. The health and economic burden of HPV
infection,
        genital warts, cervical dysplasia and cervical cancer in
Canada.
        Presented at the 7th Canadian Immunization Conference (CIC) on
        December 3, 2006 in Winnipeg.
    (4) Public Health Agency of Canada, Cervical Cancer Screening in
Canada:
        1998 Surveillance Report, Executive Summary. (Accessed at
        http://www.phac-aspc.gc.ca/publicat/ccsic-dccuac/exec_e.html).
    (5) Statement by the Society of Obstetricians and Gynaecologists
of
        Canada (SOGC) on CMAJ Commentary, "Human papillomavirus,
vaccines and
        women's health: questions and cautions". (Accessed on August
14, 2007
        at: http://www.sogc.org/media/guidelines-hpv-commentary_e.asp)
    (6) Statement by the Society of Obstetricians and Gynaecologists
of
        Canada (SOGC) on CMAJ Commentary, "Human papillomavirus,
vaccines and
        women's health: questions and cautions". (Accessed on August
14, 2007
        at: http://www.sogc.org/media/guidelines-hpv-commentary_e.asp)
    (7) Efficacy of a Prophylactic Quadrivalent Human Papillomavirus
(HPV)
        (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine for
        Prevention of Cervical Dysplasia and External Genital Lesions
(EGL).
        Presented by C. Sattler at the 45th Annual Interscience
Conference on
        Antimicrobial Agents and Chemotherapy (ICAAC) in Washington,
DC.
    (8) J Infect Dis., Prevots DR, et al, " Assessment of
Guillain-Barre
        syndrome mortality and morbidity in the United States:
implications
        for acute flaccid paralysis surveillance."
        1997 Feb;175 Suppl 1:S151-5
    (9) Canada's Chief Public Health Officer refutes Maclean's article
on HPV
        vaccine. Public Health Agency of Canada. (Accessed on August
19, 2007
        at:
 http://www.phac-aspc.gc.ca/media/cpho-acsp/hpv-vaccine070817_e.html)
    >>



For further information: Sheila Murphy, Manager, Public Affairs Merck
Frosst Canada Ltd., (514) 428-2748; Daniel Brennan, NATIONAL
PharmaCom, (514)
843-2325

In response to Merck's response ... please read the excerpt below. 

http://www.909shot.com/PressReleases/pr62706gardasil.htm

MERCK'S GARDASIL VACCINE NOT PROVEN SAFE FOR LITTLE GIRLS
National Vaccine Information Center Criticizes 

EXCERPT:   "Merck and the FDA have not been completely honest with the
people about the pre-licensure clinical trials," said NVIC president
Barbara Loe Fisher. "Merck's pre and post-licensure marketing strategy
has positioned mass use of this vaccine by pre-teens as a morality
play in order to avoid talking about the flawed science they used to
get it licensed. This is not just about teenagers having sex, it is
also about whether Gardasil has been proven safe and effective for
little girls."

The FDA allowed Merck to use a potentially reactive aluminum
containing placebo as a control for most trial participants, rather
than a non-reactive saline solution placebo.[1] A reactive placebo can
artificially increase the appearance of safety of an experimental drug
or vaccine in a clinical trial. Gardasil contains 225 mcg of aluminum
and, although aluminum adjuvants have been used in vaccines for
decades, they were never tested for safety in clinical trials. Merck
and the FDA did not disclose how much aluminum was in the placebo.[2]

Animal and human studies have shown that aluminum can cause nerve cell
death [3] and that vaccine aluminum adjuvants can allow aluminum to
enter the brain, [4 5] as well as cause inflammation at the injection
site leading to chronic joint and muscle pain and fatigue.  [6 7]
Nearly 90 percent of Gardasil recipients and 85 percent of aluminum
placebo recipients followed-up for safety reported one or more adverse
events within 15 days of vaccination, particularly at the injection
site.[8] Pain and swelling at injection site occurred in approximately
83 percent of Gardasil and 73 percent of aluminum placebo recipients.
About 60 percent of those who got Gardasil or the aluminum placebo had
systemic adverse events including headache, fever, nausea, dizziness,
vomiting, diarrhea, myalgia. [9 10] Gardasil recipients had more
serious adverse events such as headache, gastroenteritis,
appendicitis, pelvic inflammatory disease, asthma, bronchospasm and
arthritis.

"Merck and the FDA do not reveal in public documents exactly how many
9 to 15 year old girls were in the clinical trials, how many of them
received hepatitis B vaccine and Gardasil simultaneously, and how many
of them had serious adverse events after being injected with Gardasil
or the aluminum placebo. For example, if there were less than 1,000
little girls actually injected with three doses of Gardasil, it is
important to know how many had serious adverse events and how long
they were followed for chronic health problems, such as juvenile
arthritis."

According to the Merck product manufacturer insert, there was 1 case
of juvenile arthritis, 2 cases of rheumatoid arthritis, 5 cases of
arthritis, and 1 case of reactive arthritis out of 11,813 Gardasil
recipients plus 1 case of lupus and 2 cases of arthritis out of 9,701
participants primarily receiving an aluminum containing placebo.
Clinical trial investigators dismissed most of the 102 Gardasil and
placebo associated serious adverse events, including 17 deaths, that
occurred in the clinical trials as unrelated.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
http://www.909shot.com/PressReleases/pr62706gardasil.htm


MERCK'S GARDASIL VACCINE NOT PROVEN SAFE FOR LITTLE GIRLS
National Vaccine Information Center Criticizes 
FDA for Fast Tracking Licensure

Washington, D.C. - The National Vaccine Information Center (NVIC) is
calling on the CDC's Advisory Committee on Immunization Practices
(ACIP) to just say "no" on June 29 to recommending "universal use" of
Merck's Gardasil vaccine in all pre-adolescent girls. NVIC maintains
that Merck's clinical trials did not prove the human papillomavirus
(HPV) vaccine designed to prevent cervical cancer and genital warts is
safe to give to young girls.

"Merck and the FDA have not been completely honest with the people
about the pre-licensure clinical trials," said NVIC president Barbara
Loe Fisher. "Merck's pre and post-licensure marketing strategy has
positioned mass use of this vaccine by pre-teens as a morality play in
order to avoid talking about the flawed science they used to get it
licensed. This is not just about teenagers having sex, it is also
about whether Gardasil has been proven safe and effective for little
girls."

The FDA allowed Merck to use a potentially reactive aluminum
containing placebo as a control for most trial participants, rather
than a non-reactive saline solution placebo.[1] A reactive placebo can
artificially increase the appearance of safety of an experimental drug
or vaccine in a clinical trial. Gardasil contains 225 mcg of aluminum
and, although aluminum adjuvants have been used in vaccines for
decades, they were never tested for safety in clinical trials. Merck
and the FDA did not disclose how much aluminum was in the placebo.[2]

Animal and human studies have shown that aluminum can cause nerve cell
death [3] and that vaccine aluminum adjuvants can allow aluminum to
enter the brain, [4 5] as well as cause inflammation at the injection
site leading to chronic joint and muscle pain and fatigue.  [6 7]
Nearly 90 percent of Gardasil recipients and 85 percent of aluminum
placebo recipients followed-up for safety reported one or more adverse
events within 15 days of vaccination, particularly at the injection
site.[8] Pain and swelling at injection site occurred in approximately
83 percent of Gardasil and 73 percent of aluminum placebo recipients.
About 60 percent of those who got Gardasil or the aluminum placebo had
systemic adverse events including headache, fever, nausea, dizziness,
vomiting, diarrhea, myalgia. [9 10] Gardasil recipients had more
serious adverse events such as headache, gastroenteritis,
appendicitis, pelvic inflammatory disease, asthma, bronchospasm and
arthritis.

"Merck and the FDA do not reveal in public documents exactly how many
9 to 15 year old girls were in the clinical trials, how many of them
received hepatitis B vaccine and Gardasil simultaneously, and how many
of them had serious adverse events after being injected with Gardasil
or the aluminum placebo. For example, if there were less than 1,000
little girls actually injected with three doses of Gardasil, it is
important to know how many had serious adverse events and how long
they were followed for chronic health problems, such as juvenile
arthritis."

According to the Merck product manufacturer insert, there was 1 case
of juvenile arthritis, 2 cases of rheumatoid arthritis, 5 cases of
arthritis, and 1 case of reactive arthritis out of 11,813 Gardasil
recipients plus 1 case of lupus and 2 cases of arthritis out of 9,701
participants primarily receiving an aluminum containing placebo.
Clinical trial investigators dismissed most of the 102 Gardasil and
placebo associated serious adverse events, including 17 deaths, that
occurred in the clinical trials as unrelated.

"There is too little long term safety and efficacy data, especially in
young girls, and too little labeling information on contraindications
for the CDC to recommend Gardasil for universal use, which is a signal
for states to mandate it," said Fisher. "Nobody at Merck, the CDC or
FDA know if the injection of Gardasil into all pre-teen girls -
especially simultaneously with hepatitis B vaccine - will make some of
them more likely to develop arthritis or other inflammatory autoimmune
and brain disorders as teenagers and adults. With cervical cancer
causing about one percent of all cancer deaths in American women due
to routine pap screening, it was inappropriate for the FDA to fast
track Gardasil. It is way too early to direct all young girls to get
three doses of a vaccine that has not been proven safe or effective in
their age group."

The National Vaccine Information Center (NVIC), founded in 1982 by
parents of vaccine injured children, has been a leading critic of
one-size-fits-all mass vaccination policies and the lack of basic
science research into biological mechanisms and high risk factors for
vaccine-induced brain and immune system dysfunction. As a member of
the FDA Vaccines and Related Biological Products Advisory Committee
(VRBPAC), Barbara Loe Fisher urged trials include adequate safety data
on pre-adolescent children and warned against fast tracking Gardasil
at the November 28-29, 2001 VRBPAC meeting .[11]

Full 2001 FDA Transcript:
http://www.fda.gov/ohrms/dockets/ac/cber01.htm#Vaccines & Related
Biological

For more information go to www.NVIC.org.

                                -end-

1. Merck & Co., Inc. 2006. Gardasil [Quadrivalent Human Papillomavirus
Types 6,11,16,18) Recombinant Vaccine] product insert. Table 6.

2. Food and Drug Administration. May 18, 2006. FDA Background Document
for Vaccines and Related Biological Products Advisory Committee:
Gardasil HPV Quadrivalent Vaccine.

3. Kawahara M et al. 2001. Effects of aluminum on the neurotoxicty of
primary cultured neurons and on the aggregation of betamyloid protein.
Brain Res. Bull. 55, 211-217.

4. Redhead K. et al. 1992. Aluminum-adjuvanted vaccines transiently
increase aluminum levels in murine brain tissue. Pharmacol. Toxico.
70, 278-280.

5. Sahin G. et al. 1994. Determination of aluminum levels in the
kidney, liver and brain of mice treated with aluminum hydroxide. Biol.
Trace. Elem. Res. 1194 Apr-May;41 (1-2):129-35.

6. Gherardi M et al. 2001. Macrophagaic myofastitis lesions assess
long-term persistence of vaccine-derived aluminum hydroxide in muscle.
Brain, Vol 124, No. 9, 1821-1831.

7. Shingde M eta la. 2005. Macrophagic myofastitis associated with
vaccine derived aluminum. MJA, 183 (03):145-146.

8. Merck & Co. May 18, 2006. Merck briefing document for Vaccines and
Related Biological Products Advisory Committee: Gardasil. Table 24.

9. Merck & Co., Inc. 2006. Gardasil product insert: Serious Adverse
Experiences.

10. Food and Drug Administration. May 18, 2006. FDA Background
Document for Vaccines and Related Biological Products Advisory
Committee.: Gardasil. Table 32.

11. Food and Drug Administration. November 29, 2001. Vaccines and
Related Biological Products Advisory Committee. Excerpt from
transcript.

In response to Merck Myrl ... you are making a fool of yourself trying
to get the discussion off of Merck's disinformation ... while
attacking one of of Barrett's longterm targets. 

Dr. Haimes is a loving and caring doctor ... his "sins" are so
incredibly  minor compared to Oleary's, Penley Ayers, Medicor, Inamed,
Merck's, Barrett's, and Myrl Carlene Jeffcoat's ...  the amount of
your collective lies and pefidy outweigh his by a million percent.

www.BreastImplantAwareness.org/myrl.html
See Myrl as Will Ketcher

www.BreastImplantAwareness.org/quackwatchwatch.htm
Myrl publisizes their perfidy

In response to Merck's response ... please read the excerpt below. 

http://www.909shot.com/PressReleases/pr62706gardasil.htm

MERCK'S GARDASIL VACCINE NOT PROVEN SAFE FOR LITTLE GIRLS
National Vaccine Information Center Criticizes 

EXCERPT:   "Merck and the FDA have not been completely honest with the
people about the pre-licensure clinical trials," said NVIC president
Barbara Loe Fisher. "Merck's pre and post-licensure marketing strategy
has positioned mass use of this vaccine by pre-teens as a morality
play in order to avoid talking about the flawed science they used to
get it licensed. This is not just about teenagers having sex, it is
also about whether Gardasil has been proven safe and effective for
little girls."

The FDA allowed Merck to use a potentially reactive aluminum
containing placebo as a control for most trial participants, rather
than a non-reactive saline solution placebo.[1] A reactive placebo can
artificially increase the appearance of safety of an experimental drug
or vaccine in a clinical trial. Gardasil contains 225 mcg of aluminum
and, although aluminum adjuvants have been used in vaccines for
decades, they were never tested for safety in clinical trials. Merck
and the FDA did not disclose how much aluminum was in the placebo.[2]

Animal and human studies have shown that aluminum can cause nerve cell
death [3] and that vaccine aluminum adjuvants can allow aluminum to
enter the brain, [4 5] as well as cause inflammation at the injection
site leading to chronic joint and muscle pain and fatigue.  [6 7]
Nearly 90 percent of Gardasil recipients and 85 percent of aluminum
placebo recipients followed-up for safety reported one or more adverse
events within 15 days of vaccination, particularly at the injection
site.[8] Pain and swelling at injection site occurred in approximately
83 percent of Gardasil and 73 percent of aluminum placebo recipients.
About 60 percent of those who got Gardasil or the aluminum placebo had
systemic adverse events including headache, fever, nausea, dizziness,
vomiting, diarrhea, myalgia. [9 10] Gardasil recipients had more
serious adverse events such as headache, gastroenteritis,
appendicitis, pelvic inflammatory disease, asthma, bronchospasm and
arthritis.

"Merck and the FDA do not reveal in public documents exactly how many
9 to 15 year old girls were in the clinical trials, how many of them
received hepatitis B vaccine and Gardasil simultaneously, and how many
of them had serious adverse events after being injected with Gardasil
or the aluminum placebo. For example, if there were less than 1,000
little girls actually injected with three doses of Gardasil, it is
important to know how many had serious adverse events and how long
they were followed for chronic health problems, such as juvenile
arthritis."

According to the Merck product manufacturer insert, there was 1 case
of juvenile arthritis, 2 cases of rheumatoid arthritis, 5 cases of
arthritis, and 1 case of reactive arthritis out of 11,813 Gardasil
recipients plus 1 case of lupus and 2 cases of arthritis out of 9,701
participants primarily receiving an aluminum containing placebo.
Clinical trial investigators dismissed most of the 102 Gardasil and
placebo associated serious adverse events, including 17 deaths, that
occurred in the clinical trials as unrelated.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
http://www.909shot.com/PressReleases/pr62706gardasil.htm


MERCK'S GARDASIL VACCINE NOT PROVEN SAFE FOR LITTLE GIRLS
National Vaccine Information Center Criticizes 
FDA for Fast Tracking Licensure

Washington, D.C. - The National Vaccine Information Center (NVIC) is
calling on the CDC's Advisory Committee on Immunization Practices
(ACIP) to just say "no" on June 29 to recommending "universal use" of
Merck's Gardasil vaccine in all pre-adolescent girls. NVIC maintains
that Merck's clinical trials did not prove the human papillomavirus
(HPV) vaccine designed to prevent cervical cancer and genital warts is
safe to give to young girls.

"Merck and the FDA have not been completely honest with the people
about the pre-licensure clinical trials," said NVIC president Barbara
Loe Fisher. "Merck's pre and post-licensure marketing strategy has
positioned mass use of this vaccine by pre-teens as a morality play in
order to avoid talking about the flawed science they used to get it
licensed. This is not just about teenagers having sex, it is also
about whether Gardasil has been proven safe and effective for little
girls."

The FDA allowed Merck to use a potentially reactive aluminum
containing placebo as a control for most trial participants, rather
than a non-reactive saline solution placebo.[1] A reactive placebo can
artificially increase the appearance of safety of an experimental drug
or vaccine in a clinical trial. Gardasil contains 225 mcg of aluminum
and, although aluminum adjuvants have been used in vaccines for
decades, they were never tested for safety in clinical trials. Merck
and the FDA did not disclose how much aluminum was in the placebo.[2]

Animal and human studies have shown that aluminum can cause nerve cell
death [3] and that vaccine aluminum adjuvants can allow aluminum to
enter the brain, [4 5] as well as cause inflammation at the injection
site leading to chronic joint and muscle pain and fatigue.  [6 7]
Nearly 90 percent of Gardasil recipients and 85 percent of aluminum
placebo recipients followed-up for safety reported one or more adverse
events within 15 days of vaccination, particularly at the injection
site.[8] Pain and swelling at injection site occurred in approximately
83 percent of Gardasil and 73 percent of aluminum placebo recipients.
About 60 percent of those who got Gardasil or the aluminum placebo had
systemic adverse events including headache, fever, nausea, dizziness,
vomiting, diarrhea, myalgia. [9 10] Gardasil recipients had more
serious adverse events such as headache, gastroenteritis,
appendicitis, pelvic inflammatory disease, asthma, bronchospasm and
arthritis.

"Merck and the FDA do not reveal in public documents exactly how many
9 to 15 year old girls were in the clinical trials, how many of them
received hepatitis B vaccine and Gardasil simultaneously, and how many
of them had serious adverse events after being injected with Gardasil
or the aluminum placebo. For example, if there were less than 1,000
little girls actually injected with three doses of Gardasil, it is
important to know how many had serious adverse events and how long
they were followed for chronic health problems, such as juvenile
arthritis."

According to the Merck product manufacturer insert, there was 1 case
of juvenile arthritis, 2 cases of rheumatoid arthritis, 5 cases of
arthritis, and 1 case of reactive arthritis out of 11,813 Gardasil
recipients plus 1 case of lupus and 2 cases of arthritis out of 9,701
participants primarily receiving an aluminum containing placebo.
Clinical trial investigators dismissed most of the 102 Gardasil and
placebo associated serious adverse events, including 17 deaths, that
occurred in the clinical trials as unrelated.

"There is too little long term safety and efficacy data, especially in
young girls, and too little labeling information on contraindications
for the CDC to recommend Gardasil for universal use, which is a signal
for states to mandate it," said Fisher. "Nobody at Merck, the CDC or
FDA know if the injection of Gardasil into all pre-teen girls -
especially simultaneously with hepatitis B vaccine - will make some of
them more likely to develop arthritis or other inflammatory autoimmune
and brain disorders as teenagers and adults. With cervical cancer
causing about one percent of all cancer deaths in American women due
to routine pap screening, it was inappropriate for the FDA to fast
track Gardasil. It is way too early to direct all young girls to get
three doses of a vaccine that has not been proven safe or effective in
their age group."

The National Vaccine Information Center (NVIC), founded in 1982 by
parents of vaccine injured children, has been a leading critic of
one-size-fits-all mass vaccination policies and the lack of basic
science research into biological mechanisms and high risk factors for
vaccine-induced brain and immune system dysfunction. As a member of
the FDA Vaccines and Related Biological Products Advisory Committee
(VRBPAC), Barbara Loe Fisher urged trials include adequate safety data
on pre-adolescent children and warned against fast tracking Gardasil
at the November 28-29, 2001 VRBPAC meeting .[11]

Full 2001 FDA Transcript:
http://www.fda.gov/ohrms/dockets/ac/cber01.htm#Vaccines & Related
Biological

For more information go to www.NVIC.org.

                                -end-

1. Merck & Co., Inc. 2006. Gardasil [Quadrivalent Human Papillomavirus
Types 6,11,16,18) Recombinant Vaccine] product insert. Table 6.

2. Food and Drug Administration. May 18, 2006. FDA Background Document
for Vaccines and Related Biological Products Advisory Committee:
Gardasil HPV Quadrivalent Vaccine.

3. Kawahara M et al. 2001. Effects of aluminum on the neurotoxicty of
primary cultured neurons and on the aggregation of betamyloid protein.
Brain Res. Bull. 55, 211-217.

4. Redhead K. et al. 1992. Aluminum-adjuvanted vaccines transiently
increase aluminum levels in murine brain tissue. Pharmacol. Toxico.
70, 278-280.

5. Sahin G. et al. 1994. Determination of aluminum levels in the
kidney, liver and brain of mice treated with aluminum hydroxide. Biol.
Trace. Elem. Res. 1194 Apr-May;41 (1-2):129-35.

6. Gherardi M et al. 2001. Macrophagaic myofastitis lesions assess
long-term persistence of vaccine-derived aluminum hydroxide in muscle.
Brain, Vol 124, No. 9, 1821-1831.

7. Shingde M eta la. 2005. Macrophagic myofastitis associated with
vaccine derived aluminum. MJA, 183 (03):145-146.

8. Merck & Co. May 18, 2006. Merck briefing document for Vaccines and
Related Biological Products Advisory Committee: Gardasil. Table 24.

9. Merck & Co., Inc. 2006. Gardasil product insert: Serious Adverse
Experiences.

10. Food and Drug Administration. May 18, 2006. FDA Background
Document for Vaccines and Related Biological Products Advisory
Committee.: Gardasil. Table 32.

11. Food and Drug Administration. November 29, 2001. Vaccines and
Related Biological Products Advisory Committee. Excerpt from
transcript.

Coleah ... you old pushy arrogant nasty broad . You follow me all
other the internet, have hired PI's to stalk me etc. 


www.BreastImplantAwareness.org/coleah.htm

http://ilena-rosenthal.blogspot.com
www.BreastImplantAwareness.org/

I profit from knowing I have helped untold numbers of women harmed by
breast implants ...

and will profit from knowing that parents look at the facts before
allowing their children to be vaccinated with this potentially deadly
Gardasil because of my postings.

Being an advocate and activist has cost me mightily in dollars ... yet
I remain true to my missions. I have made thousands of wonderful
friends .. despite your years of efforts to harm my reputation.

You, on the other hand, are in this to destroy me ... and it is
backfiring onto you. 

You out-weigh me, out-age me, and are far richer in $$$$$$ ...but your
industry ties are ill conceived for any but the most greedy and
selfish and most low and base and ugly of purposes.

You, Coleah Penley Ayers, a loudmouth mouth for hire (or rent or even
for free sometimes) made this 'unbiased' comment about Ms Fisher, as
if you are now trying to discredit her too. 

A+ on getting the nasty strategy of Quackwatch to disparage anyone
they disagree with down pat! 

Cast doubt.
Use 'quote marks'.
Question their motives.

>You are quoting from a non-profit website and a woman 'protester against vaccinations'. 

Yes, this one.
http://www.nvic.org/

Ms Fisher has done an outstanding job in raising vaccine risk
awareness.

Concurrently, Penley Ayers has been running around like an old nutcase
on YOUR CAMPAIGN" I hate Ilena Rosenthal and You Should Too!"

Such noble work.

http://ilena-rosenthal.blogspot.com

How proud you must be. Head of the SBIPrivateClub. 

www.BreastImplantAwareness.org/sbiprivateclub.htm

BTW, on the lie about the vibrating vagina, Coleah, was this your own
work, or did someone feed you this lie and you posted it on his behalf
and then got caught looking like an idiot?
www.BreastImplantAwareness.org/coleah-lies.htm


www.nvic.org

I hope that everyone will take a look at this excellent website and
pray for the safety of Ms Fisher & her family ... especially now that
Marine for hire Coleah Penley Ayers has begun a process to discredit
her ... the first small step to harm someone used by public relations
teams.

Coleah & Myrl ... how many more years of your mutual lives are you
going to spend trying to destroy me?

How many more of your flacks are going to devote their lives to
harming mine??? 

You will not be victorious because your cause is hate-based and evil
to the bone.


www.ilena-rosenthal.blogspot.com